A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with
docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast
cancer who are candidates for taxane-based chemotherapy but who have not received prior
chemotherapy for metastatic disease. The anticipated time on treatment is 1-2 years and the
target sample size is 500+ individuals.